{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:47:55Z","timestamp":1778809675443,"version":"3.51.4"},"reference-count":34,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Development Center Americas, Inc. (TDCA)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed\/refractory (R\/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R\/R MF. (2) Methods: This observational, retrospective, cohort study analyzed patient records (1984\u20132016) from 27 clinical sites in Europe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS) and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. The median (range) times from the start of first-line therapy to the first R\/R MF and from the first to the second R\/R MF were 11.2 (0.3\u2013166.5) and 13.5 (0.0\u2013174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radiotherapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). The median (95% confidence interval [CI]) OS from the diagnosis of the first R\/R MF was 11.5 (6.5\u2013not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); the estimated median PFS (95% CI) from the time of the first R\/R MF was 1.3 (1.0\u20132.1) years. (4) Conclusions: High rates of R\/R disease were observed after second- and third-line treatments in this real-world cohort, with longer median OS in patients receiving non-chemotherapy treatment versus chemotherapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF.<\/jats:p>","DOI":"10.3390\/cancers15235669","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T07:44:42Z","timestamp":1701330282000},"page":"5669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed\/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9432","authenticated-orcid":false,"given":"Chalid","family":"Assaf","sequence":"first","affiliation":[{"name":"Department of Dermatology, Helios Klinikum Krefeld, Lutherplatz 40, 47805 Krefeld, Germany"},{"name":"Institute of Molecular Medicine, Medical School Hamburg, 20457 Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-7324","authenticated-orcid":false,"given":"Timothy M.","family":"Illidge","sequence":"additional","affiliation":[{"name":"Manchester NIHR BRC Centre, Christie Hospital, University of Manchester, Manchester M20 4BX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Waser","sequence":"additional","affiliation":[{"name":"ICON Plc, 3455 North Service Road, Unit 400, Burlington, ON L7N 3G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"He","sequence":"additional","affiliation":[{"name":"ICON Plc, 3455 North Service Road, Unit 400, Burlington, ON L7N 3G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Li","sequence":"additional","affiliation":[{"name":"ICON Plc, 3455 North Service Road, Unit 400, Burlington, ON L7N 3G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Zomas","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, CH-8152 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawal","family":"Bent-Ennakhil","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, CH-8152 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Little","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital 12 de Octubre, Institute I+12, CIBERONC, Medical School, Universidad Complutense, 28041 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section Dermatology, Hospital P. Palagi, University of Florence Medical School, Viale Michelangiolo 41, 50125 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Dalal","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02421, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[{"name":"Saint-Louis Hospital, Universit\u00e9 Paris Cit\u00e9, 1 Avenue Claude Vellefaux, 75010 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.det.2015.06.001","article-title":"Evaluation, diagnosis, and staging of cutaneous lymphoma","volume":"33","author":"Olsen","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1111\/jdv.16325","article-title":"Mycosis fungoides: Developments in incidence, treatment and survival","volume":"34","author":"Kaufman","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: Validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dobos, G., Pohrt, A., Ram-Wolff, C., Lebb\u00e9, C., Bouaziz, J.D., Battistella, M., Bagot, M., and Masson, A.D. (2020). Epidemiology of cutaneous T-cell lymphomas: A systematic review and meta-analysis of 16,953 patients. Cancers, 12.","DOI":"10.3390\/cancers12102921"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1610-0387.2007.06337.x","article-title":"Cutaneous lymphomas in Germany: An analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG)","volume":"5","author":"Assaf","year":"2007","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1684\/ejd.2017.3183","article-title":"Incidence and ten-year follow-up of primary cutaneous lymphomas: A single-centre cohort study","volume":"28","author":"Maurelli","year":"2018","journal-title":"Eur. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/bjd.19644","article-title":"Epidemiological changes in cutaneous lymphomas: An analysis of 8593 patients from the French Cutaneous Lymphoma Registry","volume":"184","author":"Dobos","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_8","unstructured":"National Cancer Registration and Analysis Service (NCRAS) (2023, January 17). National Cancer Intelligence Network (NCIN) Data Briefings, Available online: http:\/\/www.ncin.org.uk\/publications\/data_briefings."},{"key":"ref_9","first-page":"610","article-title":"The first year of the AEVD primary cutaneous lymphoma registry","volume":"109","author":"Servitje","year":"2018","journal-title":"Actas. Dermosifiliogr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"adv00013","DOI":"10.2340\/00015555-3367","article-title":"Early-stage mycosis fungoides: Epidemiology and prognosis","volume":"100","author":"Maguire","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_12","unstructured":"Mourad, M., and Gniadecki, R. (2023, November 23). Overall Survival and Prognosis in Mycosis Fungoides: A Systematic Review and Meta-Analysis. Available online: https:\/\/www.wcd2019milan-dl.org\/abstract-book\/documents\/abstracts\/39-skin-cancer\/overall-survival-and-prognosis-in-2681.pdf."},{"key":"ref_13","first-page":"1307","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"19","author":"Jonak","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11864-020-00809-w","article-title":"Mycosis fungoides and S\u00e9zary syndrome: Updates and review of current therapy","volume":"22","author":"Kamijo","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113343","DOI":"10.1016\/j.ejca.2023.113343","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome\u2014Update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC inhibitor: From cancer to cardiovascular diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam. Med. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: A multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Assaf, C., Waser, N., Bagot, M., He, M., Li, T., Dalal, M., Gavini, F., Trinchese, F., Zomas, A., and Little, M. (2021). Contemporary treatment patterns and response in relapsed\/refractory cutaneous T-cell lymphoma (CTCL) across five European countries. Cancers, 14.","DOI":"10.3390\/cancers14010145"},{"key":"ref_21","unstructured":"International Society for Pharmacoepidemiology (ISPE) (2023, January 17). Guidelines for Good Pharmacoepidemiology Practices (GPP). Available online: https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"147","author":"Altman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Campbell, B.A., Scarisbrick, J.J., Kim, Y.H., Wilcox, R.A., McCormack, C., and Prince, H.M. (2020). Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. Cancers, 12.","DOI":"10.3390\/cancers12082311"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hon.164_2631","article-title":"Survival among a patient cohort of relapsed\/refractory mycosis fungoides in France, Germany, Italy, Spain and the United Kingdom","volume":"37","author":"Bagot","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","article-title":"Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: A comparative study of systemic therapy","volume":"125","author":"Hughes","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): An international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2013.10099","article-title":"Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: Diffuse erythema as a positive predictor of complete remission","volume":"150","author":"Watanabe","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1200\/JCO.2014.57.5597","article-title":"Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: A European society for blood and marrow transplantation lymphoma working party extended analysis","volume":"32","author":"Duarte","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/bmt.2014.161","article-title":"Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome","volume":"49","author":"Lechowicz","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: Final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): A propensity score matched controlled prospective study","volume":"401","author":"Mear","year":"2023","journal-title":"Lancet."},{"key":"ref_32","first-page":"55","article-title":"Cutaneous T-Cell Lymphoma: Current and Emerging Therapies","volume":"37","author":"Dai","year":"2023","journal-title":"Oncology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_34","unstructured":"National Institute for Health and Care Excellence (NICE) (2023, January 17). A List of All Our Products on Blood and Bone Marrow Cancers. Available online: https:\/\/www.nice.org.uk\/guidance\/conditions-and-diseases\/blood-and-immune-system-conditions\/blood-and-bone-marrow-cancers\/products?ProductType=Guidance&Status=Published."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:34:56Z","timestamp":1760132096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":34,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15235669"],"URL":"https:\/\/doi.org\/10.3390\/cancers15235669","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}